Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.

The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...

CMS has a narrow, time-sensitive window to launch a national deprescribing demonstration to safely reduce or discontinue ...